原发性骨非霍奇金淋巴瘤23例临床病理分析  

Clinicopathological analyses of primary non-Hodgkins lymphoma of bone

作　　者：周志毅[1] 程静[1] 石群立[1] 周晓军[1] 田秀春[1] 肖芹[1] 周航波[1] 马恒辉[1] 

机构地区：[1]南京军区南京总医院病理科,南京210002

出　　处：《临床与实验病理学杂志》2006年第5期549-552,共4页Chinese Journal of Clinical and Experimental Pathology

摘　　要：目的探讨原发性骨非霍奇金淋巴瘤的临床病理特点、临床预后指标及Pax-5蛋白表达的诊断价值。方法复习23例骨非霍奇金淋巴瘤患者的临床资料,对血清LDH、国际预后指数及治疗与预后的关系进行分析。并用EnVision两步法标记Pax-5,比较BSAP与CD20及CD79α的表达情况。结果23骨非霍奇金淋巴瘤均为B细胞淋巴瘤,其中22例患者的5年生存率为65·9%,血清LDH升高、国际预后指数高危类对预后不利(两者P值分别为0·02和0·01)。23例中有22例表达Pax-5,Pax-5与CD20及CD79α的表达差异无统计学意义。结论骨非霍奇金淋巴瘤以B细胞淋巴瘤多见,预后较好,血清LDH和国际预后指数是判断预后的指标。Pax-5可应用于原发性骨非霍奇金淋巴瘤的诊断。Purpose To investigate the clinicopathological features, clinical prognostic indicator of primary non-Hodgkin＇s lymphoma of bone （PNHLB） , and the value of Pax-5 in diagnosis. Methods Clinical data of PNHLB was reviewed. The relations of serum LDH, international prognostic indicator （IPI） and treatment, to the outcome were analyzed. The expression of Pax-5 were detected with EnVision staining, and the result was then compared with CD20 and CD79α. Results All 23 cases were B-lymphoma. The 5- year survival rates of 22 patients were 65.9% , unfavorable variables for survival rate were higher serum LDH, high-risk IPI （ P = 0. 02, P =0.01 ）. Among 23 cases, 22 were positive for Pax-5, 2 cases of T- lymphoma were negative. The staining of Pax-5, CD20 and CD79α showed no statistical significance. Conclusions In PNHLB, B-lymphoma is most, the outcome of PNHLB is good. Serum LDH and IPI may serve as indicators for prognostic assessment. Pax-5 is applicable in the diagnosis of PNHLB.

关 键 词：骨肿瘤 淋巴瘤 非霍奇金/病理学 预后 PAX-5 

分 类 号：R733.4[医药卫生—肿瘤]